Search results
Merck Stock Jumps After Dow Jones Stalwart Rides Its Cancer 'Star' To Another Quarterly Beat
Investor's Business Daily· 2 days agoMerck Stock: Sales, Earnings Beat Overall, sales climbed 9% to $15.8 billion, topping expectations...
Merck shares target raised on strong Q1 performance By Investing.com
Investing.com· 2 days agoOn Thursday, Truist Securities adjusted the stock price target for Merck (NYSE:MRK), a global...
Analysts Set Merck & Co., Inc. (NYSE:MRK) Price Target at $131.25
ETF DAILY NEWS· 6 days agoMerck & Co., Inc. (NYSE:MRK – Get Free Report) has received a consensus recommendation of “Moderate Buy” from the twelve research firms that are presently covering the < ...
Merck stock target raised on strong Q1 results By Investing.com
Investing.com· 1 day agoOn Friday, Wells Fargo adjusted its outlook on shares of pharmaceutical giant Merck & Co., Inc....
Merck stock gains on Q1 2024 beat (NYSE:MRK)
Seeking Alpha· 2 days agoMerck (MRK) stock gains as the company posts better than expected Q1 2024 financials with strong sales growth from its cancer medicine Keytruda. Read...
Merck’s first-quarter results beat expectations amid healthy vaccine-sales growth
Market Watch· 2 days agoMerck & Co. Inc. on Thursday reported first-quarter results that beat analysts’ expectations amid...
Will Higher Keytruda Sales Drive Merck's Q1
Forbes· 4 days agoMerck (NYSE: MRK) will report its Q1 2024 results on Thursday, April 25. As usual, Keytruda will be the driving growth for Merck with quarterly sales...
Merck & Co., Inc. (NYSE:MRK) is a favorite amongst institutional investors who own 78%
Simply Wall St. via Yahoo Finance· 6 days agoKey Insights Given the large stake in the stock by institutions, Merck's stock price might be...
11 Hot Growth Stocks To Buy Right Now
Insider Monkey via Yahoo Finance· 6 days agoIn this article, we discuss the 11 hot growth stocks to buy now. If you want to read about some more growth stocks that are active in the market, go...
Merck (MRK) Q1 Earnings Top, Cancer Drug Keytruda Boosts Sales
Zacks· 3 days agoFree Report) reported adjusted earnings of $2.07 per share for first-quarter 2024, beating the Zacks Consensus Estimate of $1.94. Earnings rose 48% year over year on a reported basis and 54% ...
